Adult bovine serum (ABS) is sourced from adult cows from different regions. These sources includes North America or U.S. Origin, New Zealand Origin, Australia Origin, South America Origin, Europe Origin, etc. The procedure for production of adult bovine serum includes collection of bovine blood either from animals (cows) at the time of slaughter or from donor animals (cows). Blood taken at the slaughter house from calves or adult cattle is collected under clean, controlled conditions. The serum is separated from the blood of adult cows more than 12 months old by mechanical defibrination process. Defibrination is usually done in one of two ways. The first method is combining blood with glass beads in an airtight container, which may result in cell damage. When extended for 60 min at room temperature, it causes haemolysis. The second method involves swirling blood in a conical flask containing a glass rod covered at its lower end with glass spikes. The resultant serum is kept frozen (-20°C) in carefully identified clean, hygienic containers until it is thawed immediately prior to further processing.
Global adult bovine serum market is estimated to be valued at US$ 119.3 million in 2022 and expected to reach US$ 185.1 million by 2030, witnessing a CAGR of 5.6% over the forecast period (2022-2030).
Figure 1. Global Adult Bovine Serum Market Share (%), By Region, 2022
Increasing demand for biopharmaceuticals and vaccines is expected to drive growth of the global adult bovine serum market.
Biopharmaceutical is a medicinal product that is derived from biological sources such as animals, humans, and microorganisms using biotechnology. They are made using stem cells, mammalian cells, etc. or through tissue culture methods. Tissue culture methods make use of cell culture medium, which has many important components that maintain the integrity of the cell culture and provide nutrients and signals for the manufacturing of therapeutic recombinant molecules or biopharmaceuticals. One such component of cell culture is adult bovine serum (ABS). ABS is commonly used to supplement basal cell culture media to boost growth and proliferation of multiple cell types.
|Base Year:||2021||Market Size in 2022:||US$ 119.3 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||5.6%||2030 Value Projection:||US$ 185.1 Mn|
HiMedia Laboratories, Sartorius AG, Thermo Fisher Scientific, Auckland BioSciences Ltd., Moregate Biotech, Bovogen Biologicals, Merck KGaA, Capricorn Scientific GmbH, Gemini Bio, ROCKY MOUNTAIN BIOLOGICALS, Otto Chemie Pvt. Ltd, CellSera Australia, Serana Europe GmbH, TRINA BIOREACTIVES AG, and WISENT BIOPRODUCTS
|Restraints & Challenges:||
Over the years, demand for biopharmaceuticals and vaccines has been increasing, and this has led to an increase in demand for adult bovine serum in culture medium. For instance, according to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), 2021, a trade association that represents pharmaceutical companies all over the world, there were 2,740 drugs in development for cancer, 1,535 for immunology, 1,498 for neurology, and 1,213 for infectious diseases in 2020. According to the same source, in 2018, the research-based biopharmaceutical industry spent US$ 179 billion on research and development of biopharmaceuticals.
Figure 2. Global Adult Bovine Serum Market Share (%) Analysis, By Origin, 2022
Increasing availability of adult bovine serum sourced from different sources is expected to drive growth of the global adult bovine serum market.
Increasing availability of adult bovine serum sourced from New Zealand by key market players serum is expected to aid in the market growth over forecast period
For instance, Thermo Fisher Scientific, a U.S.-based supplier of scientific instrumentation, reagents, and consumables, offers Gibco Bovine Serum of New Zealand origin, collected from cattle typically 12-24 months of age. This serum provides exceptional value for basic cell culture, specialty research, and other diagnostic tests.
Moreover, Bovogen Biologicals, a firm dedicated to research, development, manufacturing, and delivery of high quality animal serums, provides sterile adult bovine serum of New Zealand origin, which is used as a general component in growth media for tissue and cell culture, as well as a research or diagnostic test reagent.
Global Adult Bovine Serum Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID 19) pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Supply chain and manufacturing activities have been disrupted globally, due to lockdowns implemented by governments of countries, restricted movement, and other COVID-19 safety precautions. However, demand for adult bovine serum is expected to increase during the pandemic, as ABS has applications in vaccine production.
However, manufacturing sites, which are based in worst hit countries, have been affected severely due to severe shortage of medical resources and raw materials. This has led to global supply chain disruption.
The U.S. Food and Drug Administration (FDA) continues to monitor the supply chain. The Center for Drug Evaluation and Research (CDER) Drug Shortage Staff in 2020 asked manufacturers to evaluate their entire supply chain of various products, including cell culture media, reagents, and other equipment such as centrifuge, etc. Which in future is expected to improve the supply chain of healthcare products.
Global Adult Bovine Serum Market: Restraint
Limitations associated with bovine serum in cell culture may act as a restraint for growth of the adult bovine serum market. Animal-derived components in cell culture media, such as serum, hydrolysates, growth factors, hormones, proteins, peptides, lipids, adhesion factors, and amino acids, compromise the quality and reproducibility of research. Adult bovine serum is made up of an unspecified variety of macromolecules such as hormones, transport proteins, growth factors, lipids, minerals, elements, and detoxifying factors.
Major players operating in the global adult bovine serum market include HiMedia Laboratories, Sartorius AG, Thermo Fisher Scientific, Auckland BioSciences Ltd., Moregate Biotech, Bovogen Biologicals, Merck KGaA, Capricorn Scientific GmbH, Gemini Bio, ROCKY MOUNTAIN BIOLOGICALS, Otto Chemie Pvt. Ltd, CellSera Australia, Serana Europe GmbH, TRINA BIOREACTIVES AG, and WISENT BIOPRODUCTS.
Adult bovine serum (ABS) is obtained from slaughtered adult cows. The serum is separated from the blood of adult cows more than 12 months old by mechanical defibrination process. It has double the protein level of FBS (fetal bovine serum) and contains more immunoglobulins. ABS contains a low amount of hemoglobin. ABS is often used to increase growth and proliferation of different cell types in basal cell culture media. Bovine blood taken from slaughtered cows is recycled to make a variety of products including food additives, pet food, adhesives, cosmetics, biological reagents, and pharmaceutical intermediates. Among these, serum for cell culture is the most extensively utilized product made from cow blood. The serum obtained during the slaughtering process is considered to be biologically safe for mammalian cell cultures.
Numerous benefits of using adult bovine serum for various applications such as cell culture media, vaccine production, diagnostic assays, etc. and increasing Research and development (R&D) activities for evaluating the efficiency of adult bovine serum are propelling the adult bovine serum market growth. Moreover, market players are focused on expanding vaccine manufacturing facilities, which would increase the use of adult bovine serum and drive market growth over the forecast period. For instance, in October 2021, the U.S. International Development Finance Corporation (DFC), the development bank of the U.S., and Biological E. Limited, an India-based pharmaceuticals & biologics company, announced their partnership for the expansion of Biological E.’s vaccine manufacturing facility in Hyderabad, India to produce COVID-19 vaccines. This partnership would help boost COVID-19 response efforts and also benefit long-term global health in India and throughout the Indo-Pacific region.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.